annual meeting program - American Society of Clinical Oncology

Sunday, June 6, 2010
Brd. 6 Phase II study of danusertib (D) in advanced/metastatic breast and ovarian
cancers (BC, OC). (Abstract #5014)
E. Gallerani, J. Delord, P. Schoffski, I. B. Vergote, V. N. Trillet-Lenoir, M. Maur,
M. G. Jannuzzo, A. Petroccione, G. Locatelli, D. Lorusso
Brd. 7 Immunotherapy with intraperitoneal catumaxomab in patients with advanced
ovarian cancer after a complete response to chemotherapy: A phase II study.
(Abstract #5015)
R. W. Holloway, M. Roche, L. DeMars, J. A. Williams Jr., A. Enke, A. Klein,
R. G. Linke, C. N. Krasner
Brd. 8 A KRAS variant as a biomarker of ovarian cancer risk. (Abstract #5016)
J. B. Weidhaas
Brd. 9 Clinical characteristics and outcomes of BRCA-associated ovarian cancer
(OC): Genotype and survival. (Abstract #5017)
V. Engelstaedter, M. C. Cristea, J. E. Garber, S. L. Neuhausen, P. H. Frankel,
S. Sand, L. Steele, U. Matulonis, J. Liu, J. Weitzel
Brd. 10 Breast cancer protein expression as a prognostic marker in sporadic
epithelial ovarian cancer (EOC): An NCIC CTG OV.16 correlative study.
(Abstract #5018)
J. I. Weberpals, D. Tu, J. Squire, S. Islam, S. Amin, L. Pelletier, A. O’Brien,
P. Hoskins, E. A. Eisenhauer
Brd. 11 Impact of BRCA1 gene alterations on tumor characteristics and clinical
outcome in ovarian cancer (OC) patients. (Abstract #5019)
D. Dimitrova, E. I. Braicu, R. Richter, R. Chekerov, G. Oskay-Özcelik, K. Pietzner,
A. Parashkevova, W. Lichtenegger, S. Olek, J. Sehouli, Tumor Bank Ovarian
Cancer Network
Brd. 12 Use of microarray-based comparative genomic hybridization analysis to
identify prognostic subgroups of ovarian clear cell carcinomas. (Abstract
#5020)
D. S. Tan, M. Iravani, M. B. Lambros, A. Mackay, C. Gourley, A. Williams,
W. G. McCluggage, A. Ashworth, S. B. Kaye, J. S. Reis-Filho
Brd. 13 A gene expression algorithm for the prediction of platinum sensitivity in
ovarian cancer. (Abstract #5021)
J. S. Ferriss, Y. Kim, D. Theodorescu, L. R. Duska, J. Lee
Brd. 14 Use of HE4 expression in plasma to predict operative outcome in patients
with ovarian cancer (OC). (Abstract #5022)
E. I. Braicu, R. Zeillinger, I. B. Vergote, S. Mahner, A. G. Zeimet, I. Cadron,
D. Castillo-Tong, R. Chekerov, B. Brandt, J. Sehouli
Brd. 16 Performance of PREMM1,2,6, MMRpredict, and MMRpro in detecting Lynch
syndrome among endometrial cancer cases. (Abstract #5024)
R. C. Mercado, H. Hampel, R. Mopala, F. Kastrinos, E. W. Steyerberg, J. Balmaña,
D. E. Cohn, F. J. Backes, A. De La Chapelle, S. Syngal, Colon Cancer Family
Registry (CCFR)
Brd. 17 Impact of microsatellite instability in overall survival of women with
endometrial cancer. (Abstract #5025)
J. C. Rocha, C. B. Chaves, V. P. Leite, F. C. Moreira, D. M. Ramalho
Brd. 18 Evaluation of insulin resistance among endometrial cancer patients.
(Abstract #5026)
J. K. Burzawa, K. M. Schmeler, M. W. Bevers, T. B. Pustilnik, J. Brown,
M. L. Anderson, L. M. Ramondetta, D. Urbauer, G. Tortolero-Luna, K. H. Lu
Brd. 19 Influence of radiation modality and nodal dissection on survival in high-risk
early-stage endometrial cancer. (Abstract #5027)
J. P. Chino, E. Jones, A. Berchuck, L. Havrilesky
Brd. 20 Adjuvant chemotherapy and chemoradiation following surgery for high-risk
endometrial cancer. (Abstract #5028)
K. Narayan, D. Rischin, M. Quinn, J. C. Goh, R. Cheuk, A. Obermair, D. Bernshaw,
B. McClure, A. Milner, L. R. Mileshkin
251
SUNDAY